Infectious diseases are becoming more frequent, more severe, and harder to control in our closely connected world. Viruses ...

Researchers at Rutgers University have created a new antiviral drug for COVID-19 that could be safer and more effective than Paxlovid, the current leading treatment. The new drug, called Jun13296, may ...

Low vaccination rates for influenza viruses and the lack of an HSV vaccine underscore the need for a new approach to reduce viral transmission. Researchers have now used a clinical-grade antiviral ...

This development comes at a time when pharmaceutical firms are discontinuing discovery efforts in next-generation COVID-19 ...

Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment.

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

We want wide, fast, and affordable access for our new antiviral. It might sound counterintuitive, but a patent will help us ...

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the 12 months ended December 31, 2024, and provides updates on its antiviral product pipeline, ...

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.